NASDAQ: KPRXKiora Pharmaceuticals Inc Stock
$3.83+0.03 (+0.79%)
Updated Jan 24, 2025
KPRX Price
$3.83
Fair Value Price
$4.36
Market Cap
$11.49M
52 Week Low
$3.00
52 Week High
$8.98
P/E
1.04x
P/B
0.38x
P/S
0.96x
PEG
N/A
Dividend Yield
N/A
Revenue
$16.02M
Earnings
$5.55M
Gross Margin
100%
Operating Margin
35.28%
Profit Margin
34.6%
Debt to Equity
0.28
Operating Cash Flow
$8M
Beta
0.79
Next Earnings
Mar 24, 2025
Ex-Dividend
N/A
Next Dividend
N/A
KPRX Overview
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KPRX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Value
C
Growth
D
Momentum
C
Sentiment
D
Safety
C
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
KPRX
Ranked#129 of 555
Ranked#129 of 555
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $22.17 | A | |
| $122.04 | A | |
| $2.96 | A |
Be the first to know about important KPRX news, forecast changes, insider trades & much more!
KPRX News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KPRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KPRX ($3.83) is undervalued by 12.23% relative to our estimate of its Fair Value price of $4.36 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
KPRX ($3.83) is not significantly undervalued (12.23%) relative to our estimate of its Fair Value price of $4.36 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KPRX was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KPRX due diligence checks available for Premium users.
Valuation
KPRX fair value
Fair Value of KPRX stock based on Discounted Cash Flow (DCF)
Price
$3.83
Fair Value
$4.36
Undervalued by
12.23%
KPRX ($3.83) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KPRX ($3.83) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KPRX was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KPRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
1.04x
Industry
-188.16x
Market
30.33x
KPRX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
KPRX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
KPRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.38x
Industry
5.04x
KPRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KPRX's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.4M
Profit Margin
0%
KPRX's Earnings (EBIT) of $5.65M... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$38.5M
Liabilities
$8.5M
Debt to equity
0.28
KPRX's short-term assets ($31.65M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KPRX's short-term assets ($31.65M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KPRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
KPRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$920.1k
Investing
-$1.9M
Financing
$0.0
KPRX's operating cash flow ($8.23M)... subscribe to Premium to read more.
Debt Coverage Financials
KPRX vs Biotech Stocks
Kiora Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.